ArticleTherapeutic advances in medical oncology2025
Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pembrolizumab plus chemotherapy (Pembrolizumab-CT) has been suggested as first-line treatment over pembrolizumab alone in aggressive non-small-cell lung cancer (NSCLC) with ⩾50% PDL1, but studies comparing these two strategies are lacking. Objectives: To compare overall survival under pembrolizumab and Pembrolizumab-CT depending on tumor aggressiveness in PDL1 ⩾50% advanced NSCLC patients. Design: A multicenter retrospective study was conducted of all patients with advanced NSCLC, PDL1 ⩾50% and ECOG 0-1, who received pembrolizumab or Pembrolizumab-CT as first-line treatment. Methods: Tumor aggressiveness was defined as a sum of longest diameters (SLD) ⩾ 100 mm, a largest lesion diameter (LLD) >60 mm, ECOG 1, or need for corticosteroid therapy. Overall survival was analyzed in the whole population and in subgroups as restricted mean survival time (RMST) adjusted for the main prognostic variables. Results: Ninety-six of the 164 included patients (58.5%) received pembrolizumab, and 68 (41.5%) received Pembrolizumab-CT. In the study group overall, the RMST was significantly shorter under Pembrolizumab-CT than under pembrolizumab (-7.9 months; Conclusion: Pembrolizumab-CT was not associated with improved survival compared with pembrolizumab alone, in PDL1 ⩾ 50% advanced NSCLC patients, even in cases of aggressive disease. Chemotherapy-related toxicities may have had a negative effect on survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.